

PHARMACEUTICAL 2023



FIBROGEN INC Rank 338 of 446







PHARMACEUTICAL 2023

FIBROGEN INC

Rank 338 of 446



The relative strengths and weaknesses of FIBROGEN INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of FIBROGEN INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 19% points. The greatest weakness of FIBROGEN INC is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is -49%, being 92% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	492,826
Cost of Goods Sold	20,280
Intangible Assets	0
Liabilities, Current	273,562
Liabilities, Non-Current	271,755
Other Assets	96,656
Other Compr. Net Income	-1,557
Other Expenses	358
Other Liabilities	66,250
Other Net Income	7,729
Other Revenues	140,734
Property and Equipment	20,605
Research and Development	296,791
Selling, General and Administrative Expense	124,688

Output Variable	Value in 1000 USD
Assets	610,087
Liabilities	611,567
Expenses	442,117
Revenues	140,734
Stockholders Equity	-1,480
Net Income	-293,654
Comprehensive Net Income	-294,432
Economic Capital Ratio	-49%

